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Abstract
Purpose Infectious diseases are more frequent and can be associated with worse outcomes in patients with diabetes. The aim of
this study was to systematically review and conduct a meta-analysis of the available observational studies reporting the effect of
diabetes on mortality among hospitalized patients with COVID-19.
Methods The Medline, Embase, Google Scholar, and medRxiv databases were reviewed for identification of eligible studies. A
random effects model meta-analysis was used, and I2 was utilized to assess the heterogeneity. In-hospital mortality was defined as
the endpoint. Sensitivity, subgroup, and meta-regression analyses were performed.
Results A total of 18,506 patients were included in this meta-analysis (3713 diabetics and 14,793 non-diabetics). Patients with
diabetes were associated with a higher risk of death compared with patients without diabetes (OR 1.65; 95% CI 1.35–1.96; I2
77.4%). The heterogeneity was high. A study-level meta-regression analysis was performed for all the important covariates, and
no significant interactions were found between the covariates and the outcome of mortality.
Conclusion This meta-analysis shows that that the likelihood of death seems to be higher in diabetic patients hospitalized with
COVID-19 compared with non-diabetic patients. Further studies are needed to assess whether this association is independent or
not, as well as to investigate the role of adequate glycemic control prior to infection with COVID-19.
Keywords COVID-19 . SARS-CoV-2 . Diabetes . Mortality . Risk factor . Meta-analysis
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Introduction
Diabetes mellitus is one of the leading causes of morbidity and
mortality worldwide and is associated with significant cardiovascular and renal complications. The estimated global prevalence was 9.3% in 2019 with an upward trend [1, 2]. In the
USA alone, more than 34 million adults had known or undiagnosed diabetes in 2018 [3]. In 2017, diabetes was listed as
the underlying or contributing cause of death on 270,702
death certificates, which corresponds to a crude rate of 83.1
per 100,000 persons [3].
Infectious diseases are more frequent and can be associated
with worse outcomes in patients with diabetes [4]. Therefore,
it is not surprising that diabetes has been considered as a
possible risk factor or a predictor for worse outcomes in patients with coronavirus disease 2019 (COVID-19) [5–7].
COVID-19 rapidly reached the level of a pandemic and has
caused more than 850,000 deaths worldwide within a few
months despite unprecedented mitigation measures [8]. The
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strength of the association between diabetes and COVID-19
has been investigated in observational cohorts around the
world.
We aimed to systematically review and conduct a metaanalysis of the available observational studies reporting the
effect of diabetes on mortality among hospitalized patients
with COVID-19.

Materials and methods
This study was performed according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) [9], although only observational studies were
included.

Literature search
We conducted a systematic literature search of the Medline,
Embase, Google Scholar, and medRxiv (the preprint server
for health sciences) databases up to May 10, 2020 for observational studies providing data concerning any kind of association between diabetes and mortality in hospitalized patients
with COVID-19. The reference lists of the possibly eligible
articles and the relevant secondary research studies were
reviewed manually. Two investigators (LP and DGK) independently searched for eligible studies. In cases where there
was a disagreement regarding the eligibility of a study, a third
investigator (FZ) was involved in order for consensus to be
reached. The reference list of pertinent reviews and observational studies were also manually searched for further potentially eligible studies. A combination of the following keywords was used to perform our search: “COVID-19,”
“SARS-CoV-2,” “novel coronavirus,” “risk factor,” “mortality,” and “death.” The search algorithms that were used for
each database are provided in Supplementary Methods. The
pre-specified inclusion criteria were as follows: (i) studies
which included adult patients hospitalized for COVID-19
and (ii) studies that provided data on any kind of association
between diabetes and mortality in the aforementioned population. The pre-specified exclusion criteria were as follows: (i)
certainly or possibly duplicated or overlapping patient populations and (ii) studies that included pre-specified patient populations based on a specific diagnosis (e.g., only hypertensives
or only patients with cancer). In the case of duplicated or
overlapping populations, the studies with a larger sample size
were included.

Data extraction and outcomes
Data extraction was performed based on a pre-defined data
extraction form by two independent investigators (NCP and

WL) blinded to each other. The pre-specified outcome was inhospital mortality.

Risk of bias assessment
Two independent reviewers (NCP and PM) assessed the risk
of bias of the included studies with the Quality in Prognosis
Studies (QUIPS) tool [10]. Studies were assessed as having
low, moderate, serious, or critical risk of bias for the following
domains: study participation, study attrition, prognostic factor
measurement, confounding measurement and account, outcome measurement, analysis, and reporting.

Statistical analysis
We estimated the odds ratios (ORs) and their respective 95%
confidence intervals (CI) for all the individual studies. When
neither OR nor event rates were provided, we used the unadjusted hazard ratios and converted them to ORs given the short
follow-up period. For studies that provided both adjusted and
unadjusted ORs, we used the unadjusted effect estimate. We
performed a meta-analysis using the random effects model
according to the method of Der Simonian and Laird.
Heterogeneity among trials for each outcome was assessed
with the I2 test. Values < 25% indicated low, 25 to 70% moderate, and > 70% high heterogeneity [11]. Egger’s test and
funnel plots were used to assess for publication bias.
Subgroup and sensitivity analyses were performed based on
the location where the studies were conducted and the mean/
median age. A meta-regression analysis was performed for
important covariates in order to address high heterogeneity
among the included studies. Statistical significance level was
set at 0.05 with CI calculated at the 95% level. Stata 14.1
(Stata Corp., College Station, TX, USA) was used for statistical analysis.

Results
Out of 1721 studies screened from the literature and online
sources, 14 observational studies (12 retrospective and two
prospective) met the pre-specified criteria for inclusion in
the analysis (Fig. 1) [12–25]. The characteristics of these
studies are summarized in Table 1. Overall, all the studies
were found to have a low risk of bias (Fig. 2). Five studies
were conducted in Asia, five in the USA, and four in
Europe. The total number of patients included in the final
dataset was 18,506 patients, 3713 being diabetics and
14,793 non-diabetics. The mean or median age was above
60 years in 12 studies; 43% (7967) of the population were
women (Table 2). Among studies which reported their results in event rates, the overall frequency of death events in
diabetics was 41.1% (991 out of 2413) compared with
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Table 1

Characteristics of the included studies

Study

Country Region

Institution

Study design

Guan

China

Multicenter

Retrospective December 25 January 31

Han
Zeng

China
China

Tongji Hospital
Multicenter (not Tongji
Hospital)
Baqiyatallah Hospital
Babol University of
Medical Sciences
Multicenter
La Paz University Hospital
Imperial College Healthcare
NHS Trust
North Bristol NHS Trust
Northwell Health
Mount Sinai Health System

Retrospective February 2
Retrospective February 5

February 15 306
March 20
97

Retrospective February 19
Retrospective February 25

April 15
March 12

2964
100

Prospective
February 27
Retrospective February 25
Retrospective February 25

April 2
April 19
April 5

1075a
2226
520

Retrospective March 1
Retrospective March 1
Retrospective March 7

March 30
April 12
April 15

95
5233
3273

Prospective
March 2
Retrospective March 9
Retrospective March 1

April 1
March 22
April 6

257
200
570b

31 regions (including
Wuhan)
Wuhan
Xi’an and Wuhan

Nikpouraghdam Iran
Javanian
Iran

Tehran
Babol

Rossi
Borobia
Perez Guzman

Italy
Spain
UK

Reggio Emilia
Madrid
London

Tomlins
Levy
Wang

UK
USA
USA

Bristol
New York
New York

Cummings
Palaiodimos
Bode

USA
USA
USA

New York
New York-Presbyterian
New York
Montefiore Medical Center
10 states (not New York) Multicenter

a

Only the subset of patients who were hospitalized were included

b

Only the subset of patients who had been discharged or died were included

17.6% (2113 out of 12,012) in the non-diabetic group. (The
numbers of death events in the groups of interest were not
provided in three studies; instead, odds or hazard ratios
were provided) In our meta-analysis of 14 studies, we found
that patients with diabetes were associated with a higher
risk of death compared with patients without diabetes, but
with significant heterogeneity (OR 1.65; 95% CI 1.35–
1.96; I2 77.4%; Fig. 3).

First patient

Last patient

Number of
included patients
1590

Publication bias assessment findings
Assessment for publication bias was performed in two different
ways. Visual assessment of the funnel plot suggested possible
publication bias given the asymmetry noted among smaller studies. However, Egger’s test was non-significant; thus, it was not
suggestive of publication bias (p = 0.255) (Fig. 5).

Meta-regression analysis
Sensitivity and subgroup analyses
Sensitivity analyses were conducted for studies that were performed in the USA (N = 5), Asia (5), and Western countries
(Europe-USA) (N = 9). Similarly, in the overall analysis, our
sensitivity analysis for studies conducted in the USA revealed
a greater risk of death among diabetic patients compared with
the non-diabetes group (OR 1.34; 95% CI 1.04–1.85; I2
73.7%). We found a similar association for studies conducted
in Asia (OR 2.12; 95% CI 1.09–3.16; I2 61.1%) and among
studies conducted in the Western countries (USA or Europe)
(OR 1.60; 95% CI 1.27–1.93; I2 82.8%; Fig. 4). Subgroup
analysis of the studies that had a mean or median age less than
60 years (N = 2, both from Asia) did not show a significant
difference in mortality between diabetics and non-diabetics
(OR 2.3; 95% CI 0.01–4.92; I2 75.5%; Fig. 4) but were likely
limited by the small sample given the wide range in confidence intervals.

A study-level meta-regression analysis was performed for all
the important covariates (age: p = 0.474, female sex: p =
0.766, hypertension: p = 0.524, coronary artery disease: p =
0.808, heart failure: p = 0.263, chronic kidney disease: p =
0.875, history of stroke: p = 0.252, smoking history: p =
0.639, COPD history: p = 0.620, and malignancy history:
p = 0.329). No significant interactions were found between
the covariates mentioned above and the outcome of mortality.
The detailed meta-regression results can be found in Table 3.

Discussion
Our study was a systematic review and meta-analysis of observational studies looking at the association between diabetes
and mortality in adult hospitalized patients with COVID-19.
The findings of our study can be summarized as follows: (i)
overall, death was 65% more likely to occur in diabetic

674 (42.7)
132 (43.1)
38 (39.2)
1009 (34.0)
49 (49.0)
418 (38.9)
1152 (51.8)
198 (38.0)
35 (37.0)
2176 (41.6)
1399 (42.7)
87 (34.0)
102 (51.0)

48.9 ± 16.3a
60 (49–70)b
67 (57–75)b
55.5 ± 15.2a
60.1 ± 13.9a
63.2c
61 (46–78)b
67 (41–93)b
75 (59–82)b
21–106d
60 (46–71) vs. 75 (65–84)e

62 (51–72)b
64 (50–73.5)b

65 (24–95) vs. 61 (18–101)f 498 (44.4)

Guan
Han
Zeng
Nikpouraghdam
Javanian
Rossi
Borobia
Perez Guzman
Tomlins
Levy
Wang

Cummings
Palaiodimos

Bode

NA
NA
NA
NA
NA
85 (7.9)
NA
82 (16.0)
NA
NA
NA

NA

NA

162 (63.0) NA
152 (76.0) 92 (46.2)

269 (16.9)
119 (38.9)
47 (48.5)
59 (1.9)
32 (32.0)
280 (26.0)
920 (41.3)
187 (36.0)
35 (37.0)
2474 (50.2)
1082 (33.0)

NA

NA
33 (16.5)

NA
4 (1.3)
8 (8.2)
18 (0.6)
12 (12.0)
45 (4.2)
174 (7.8)
70 (13.4)
22 (23.0)
326 (6.6)
NA

NA

NA

NA
37 (14.0)
34 (17.0) 58 (29.0)

59 (3.7)
NA
25 (8.2)
NA
NA
NA
37(1.3)
NA
NA
NA
115 (10.6) 96 (8.9)
NA
NA
43 (8.2)
21 (4.0)
21 (22.0) 15 (16.0)
454 (9.2) 219 (4.4)
NA
NA

NA

NA
22 (11.0)

30 (1.9)
11 (3.6)
NA
NA
3 (3.0)
NA
NA
34 (6.5)
8 (8.4)
NA
NA

NA

NA
65 (32.5)

111 (7.0)
5 (1.6)
NA
NA
NA
NA
157 (7.1)
NA
NA
NA
116 (3.5)

HTN (n, %) HLD (n, %) CAD (n, %) HF (n, %) CKD (n, %) CVA (n, %) Smoking (n,
%)

NA

24 (9.0)
28 (14.0)

24 (1.5)
18 (5.9)
8 (8.2)
60 (2.0)
12 (12.0)
91 (8.5)
153 (6.9)
20 (3.8)
10 (11.0)
NA
NA

NA

18 (7.0)
11 (5.5)

NA
18 (5.9)
NA
17 (0.6)
4 (4.0)
167 (15.5)
385 (17.3)
46 (8.8)
20 (21.0)
NA
233 (7.1)

COPD (n, %) Malignancy (n,
%)

f

e

d

c

b

a

Median (range) in diabetics vs. non-diabetics

Median (IQR) in discharged vs. deceased

Range

Mean

Median (IQR)

Mean ± SD

Abbreviations: DM diabetes mellitus, HTN hypertension, HLD hyperlipidemia, CAD coronary artery disease, HF heart failure, CKD chronic kidney disease, CVA cerebrovascular accident, COPD chronic
obstructive pulmonary, NA non-available

92 (35.8)
79/200
(39.5)
184 (32.3)

130 (8.2)
129 (42.2)
26 (26.8)
113 (3.8)
37 (37.0)
175 (16.3)
381 (17.1)
138 (26.5)
37/95 (38.9)
1414 (27.0)
768 (23.5)

Female (n, %) DM (n, %)

Age

Baseline characteristics of patients per included study

Study

Table 2
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Identification

Hormones

Records idenﬁed through PubMed
(n = 1550), Embase (n=1491), Google
Scholar (n=1659), and medRxiv
(n=38) searches

Addional records idenﬁed
through manual search
(n = 6)

Included

Eligibility

Screening

Records aer duplicates removed
(n = 1721)

Records screened
(n = 1721)

Records excluded
(n = 1651)

Full-text arcles assessed
for eligibility
(n = 70)

Full-text arcles excluded,
with reasons
(n = 43)

Studies considered eligible
inially
(n = 27)

Studies with possible
duplicated populaons
(n = 13)

Studies included in
quantave synthesis
(meta-analysis)
(n = 14)

Fig. 1 PRISMA 2009 flow diagram

inpatients compared with non-diabetic patients but was limited by significant heterogeneity; (ii) this association remained
significant when the analysis focused on geographical regions
of study origin with, once again, significant heterogeneity;
and (iii) our meta-regression analysis did not show an association between how frequent the other significant comorbidities were across different studies and our results.
The findings of our meta-analysis are consistent with the
results of several large observational cohorts. In one of the largest retrospective studies of hospitalized patients with COVID-19
conducted in New York, diabetic patients comprised 33.8%
(1808/5700) of the total inpatient population [26], whereas the
prevalence of diabetes in the general population in New York is
approximately 10.5% [27]. An early cohort of 1099 patients
with COVID-19 from China revealed that 17.8% of the entire
cohort developed severe disease, while the respective rate in the
diabetic subgroup was 34.6% [28]. In contrast, a large study also

from New York, which included 4103 patients, showed that
diabetes was not an independent risk factor for the development
of critical illness from COVID-19, although a trend was noted
(OR 1.14, 95% CI 0.83–1.58) [29]. Smaller cohorts included in
this meta-analysis did not show an association of diabetes with
in-hospital mortality, but these studies had relatively small sample sizes and were likely underpowered (19, 23, 24). Given the
heterogeneity of the results across the literature, our metaanalysis sought to answer this significant question by utilizing
a total sample of 18,506 patients.
Diabetes is associated with higher susceptibility to infectious diseases and higher infection-related mortality [30]. A
retrospective matched control study from Canada of more
than one million participants demonstrated that diabetics had
a significantly higher risk of being hospitalized due to an
infection, develop sepsis, and die regardless of the affected
system or organ or whether the infection was viral or bacterial
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Fig. 2 Risk of bias assessment
based on the Quality in Prognosis
Studies (QUIPS) tool

[31]. Similarly, a UK cohort of more than 100,000 diabetics
and 200,000 control subjects revealed that diabetic patients
had significantly higher rates of all types of infections with
Fig. 3 Overall analysis: diabetes
vs. no diabetes for in-hospital
mortality

an almost double risk for hospitalization and death compared
with non-diabetics [32]. Among others, diabetics had 40%
higher rates of lower respiratory infections (101.1 vs. 73.3;
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Fig. 4 Sensitivity and subgroup analyses based on the region of the study origin and the mean/median age of the study population: diabetes vs. no
diabetes for in-hospital mortality

Fig. 5 Funnel plot for assessment
of publication bias. Funnel plot is
asymmetric among smaller
studies suggesting possible
publication bias. However,
Egger’s test was non-significant,
thus, it was not suggestive of
publication bias (p = 0.255)
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Table 3

Results of the meta-regression analysis

Variables

Coefficient

Standard error

p value

Age
Female
HTN
CAD
HF
CKD
CVA
Smoking
COPD
Malignancy

− 0.019
− 0.003
− 0.005
0.594
0.026
− 0.003
− 0.078
− 0.012
− 0.022
0.025

0.026
0.010
0.007
0.361
0.019
0.018
0.058
0.024
0.043
0.024

0.474
0.766
0.524
0.808
0.263
0.875
0.252
0.639
0.620
0.329

Abbreviations: HTN hypertension, CAD coronary artery disease, HF
heart failure, CKD chronic kidney disease, CVA cerebrovascular accident,
COPD chronic obstructive pulmonary disease

per 1000 patients/year) [32]. In the 2009 H1N1 pandemic, it
was noted that diabetes tripled the risk of hospitalization and
quadrupled the risk of admission to intensive care units [33].
Reduced T lymphocyte response, decreased neutrophil
function, impaired humoral immunity, increased adherence
of microorganisms to diabetic cells, and increased virulence
of some microorganisms in patients with hyperglycemia are
some of the pathogenetic mechanisms that likely make diabetics more susceptible to infectious diseases [4, 34]. In addition, diabetes is a major cause of endothelial dysfunction [35].
The increasing evidence of endothelial involvement in severe
COVID-19 [36, 37], which potentially contributes to COVID19-associated coagulopathy [38], could raise the hypothesis
that dysfunctional endothelium is more susceptible to further
damage related to COVID-19.
The main strengths of our study are the strict methodology,
robust analysis, and relatively large number of included studies and overall patient sample. Notably, three continents and
most of the countries that had high COVID-19 incidence were
represented. Sensitivity, subgroup, and meta-regression analyses were performed as needed.
The main limitation of our study is the lack of data on
glycemic control prior to infection with COVID-19 or during
hospitalization. Therefore, we could not estimate the associations of controlled and uncontrolled diabetes with in-hospital
mortality and we recognize that the association could likely be
stronger in patients with uncontrolled diabetes and weaker in
patients with controlled diabetes. A patient-level meta-analysis would be needed to assess this very important parameter.
Second, the estimated association is not adjusted for other
important covariates. Unfortunately, only three of the included
studies provided adjusted effect estimates with a total of only
977 patients. Pooling the adjusted estimates from these three
studies did not show an independent association between diabetes and higher in-hospital mortality, likely because of low

statistical power. However, a trend towards significance was
observed (OR 1.29; 95% CI 0.87–1.71; I 2 0.00%;
Supplementary Figure 1). We tried to solve this methodological issue by performing a meta-regression analysis, which
demonstrated that the different rates of the other major comorbidities across different studies did not have an impact on the
results. Similarly, a patient-level meta-analysis would be the
ideal way to adjust for other significant covariates. Third, our
meta-analysis was limited by significant heterogeneity, which
we tried to assess by using a random effects model,
performing subgroups and sensitivity, and meta-regression
analysis. Fourth, we followed the PRISMA guidelines instead
of the MOOSE guidelines [39]. The latter would be more
appropriate given the fact that only observational studies were
included in this systematic review and meta-analysis.
In conclusion, the present systematic review and metaanalysis revealed that the likelihood of death seems to be higher
in diabetic hospitalized patients with COVID-19 compared
with non-diabetics. Although the heterogeneity was substantial,
meta-regression analysis did not reveal any significant confounders. Further studies are needed to assess whether this
association is independent or not as well as to investigate the
role of optimal glycemic control prior to or during the disease.
The findings of our study also highlight the importance of
preventing and controlling diabetes and its complications to
protect this vulnerable population from COVID-19 given the
increased risk for adverse outcomes. In addition, attention
should be paid to the importance of controlling hyperglycemia
in diabetic patients diagnosed with COVID-19 given the possible higher risk for adverse outcomes. While we recognize the
limitations, we hope that our study will compliment further
research of the effect of diabetes in COVID-19.
Data availability Yes, upon request to the first author.

Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Ethics approval Not applicable.
Consent to participate Not applicable.
Consent for publication All authors approved this manuscript.
Code availability Yes, upon request to the first author

References
1.

Zhou B, Lu Y, Hajifathalian K, Bentham J, Di Cesare M, Danaei G,
Bixby H, Cowan MJ, Ali MK, Taddei C, Lo WC (2016)
Worldwide trends in diabetes since 1980: a pooled analysis of

Hormones

2.

3.

4.

5.

6.

7.

8.
9.

10.

11.
12.

13.

14.

15.

16.

17.

751 population-based studies with 4.4 million participants. Lancet
387(10027):1513–1530
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin
N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE
(2019) Global and regional diabetes prevalence estimates for 2019
and projections for 2030 and 2045: results from the International
Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract 157:
107843
Centers for Disease Control and Prevention (2020) National diabetes statistics report. US Department of Health and Human Services.
https://www.cdc.gov/diabetes/data/statistics-report/index.html.
Accessed 20 June 2020
Casqueiro J, Casqueiro J, Alves C (2012) Infections in patients with
diabetes mellitus: a review of pathogenesis. Indian J Endocrinol
Metab 16(Suppl1):S27. https://doi.org/10.4103/2230-8210.94253
Hussain A, Bhowmik B, do Vale Moreira NC (2020) COVID-19
and diabetes: knowledge in progress. Diabetes Res Clin Pract 162:
108142. https://doi.org/10.1016/j.diabres.2020.108142
Maddaloni E, Buzzetti R (2020) Covid-19 and diabetes mellitus:
unveiling the interaction of two pandemics. Diabetes Metab Res
Rev:e33213321. https://doi.org/10.1002/dmrr.3321
Angelidi AM, Belanger MJ, Mantzoros CS (2020) COVID-19 and
diabetes mellitus: what we know, how our patients should be treated now, and what should happen next. Metabolism 107:154245.
https://doi.org/10.1016/j.metabol.2020.154245
WHO (2020) Coronavirus disease (COVID-19) dashboard. https://
covid19.who.int/. Accessed: August 10, 2020
Moher D, Liberati A, Tetzlaff J, the PRISMA group (2009)
Preferred reporting items for systematic reviews and meta-analyses:
the PRISMA statement. Ann Intern Med 151:264–269
Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier
C (2013) Assessing bias in studies of prognostic factors. Ann Intern
Med 158(4):280–286
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a
meta-analysis. Stat Med 21(11):1539–1558
Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu
XQ, Chen RC, Tang CL, Wang T, Ou CQ (2020) Comorbidity and
its impact on 1590 patients with Covid-19 in China: a nationwide
analysis. Eur Respir J 55(5):2000547
Han M, Ma K, Wang X, Yan W, Wang H, You J, Wang Q, Chen H,
Wang J, Chen L, Xu D (2020) Higher fasting plasma glucose reduced the survival rate of 306 hospitalized patients with COVID-19
in Wuhan. China SSRN. https://doi.org/10.2139/ssrn.3576809
Zeng X, Fan H, Lu D, Huang F, Meng X, Li Z, Tang M, Zhang J,
Liu N, Liu Z, Zhao J (2020) Association between ABO blood
groups and clinical outcome of coronavirus disease 2019: evidence
from two cohorts. medRxiv:20063107. https://doi.org/10.1101/
2020.04.15.20063107
Nikpouraghdam M, Farahani AJ, Alishiri G, Heydari S,
Ebrahimnia M, Samadinia H, Sepandi M, Jafari NJ, Izadi M,
Qazvini A, Dorostkar R (2020) Epidemiological characteristics of
coronavirus disease 2019 (COVID-19) patients in IRAN: a single
center study. J Clin Virol 127:104378. https://doi.org/10.1016/j.
jcv.2020.104378
Javanian M, Bayani M, Shokri M, Sadeghi-Haddad-Zavareh M,
Babazadeh A, Yeganeh B, Mohseni S, Mehraein R, Sepidarkish
M, Bijani A, Rostami A (2020) Clinical and laboratory findings
from patients with COVID-19 pneumonia in Babol North of Iran:
a retrospective cohort study. Rom J Intern Med 58(3):161–167.
https://doi.org/10.2478/rjim-2020-0013
Rossi PG, Marino M, Formisano D, Venturelli F, Vicentini M,
Grilli R, Reggio Emilia COVID-19 Working Group (2020)
Characteristics and outcomes of a cohort of SARS-CoV-2 patients
in the Province of Reggio Emilia, Italy. PLoS One 15(8):e0238281.
https://doi.org/10.1371/journal.pone.0238281

18.

Borobia AM, Carcas AJ, Arnalich F, Alvarez-Sala R, Montserrat J,
Quintana M, Figueira JC, Santos-Olmo RM, Garcia-Rodriguez J,
Martin-Vega A, Ramirez E (2020) A cohort of patients with
COVID-19 in a major teaching hospital in Europe. J Clin Med
9(6):1733. https://doi.org/10.3390/jcm9061733
19. Perez Guzman PN, Daunt A, Mukherjee S, Crook P, Forlano R,
Kont M, Lochen A, Vollmer M, Middleton P, Judge R, Harlow C
(2020) Clinical characteristics and predictors of outcomes of hospitalized patients with COVID-19 in a multiethnic London NHS
Trust: a retrospective cohort study. Clin Infect Dis ciaa1091.
https://doi.org/10.1093/cid/ciaa1091
20. Tomlins J, Hamilton F, Gunning S, Sheehy C (2020) Clinical features of 95 sequential hospitalized patients with novel coronavirus
2019 disease (COVID-19), the first UK cohort. J Inf Secur 81(2):
e59–e61. https://doi.org/10.1016/j.jinf.2020.04.020
21. Levy TJ, Richardson S, Coppa K, Barnaby DP, McGinn T, Becker
LB, Davidson KW, Hirsch JS, Zanos T (2020) Development and
validation of a survival calculator for hospitalized patients with
COVID-19. medRxiv. https://doi.org/10.1101/2020.04.22.
20075416
22. Wang Z, Zheutlin AB, Kao YH, Ayers KL, Gross SJ, Kovatch P,
Nirenberg S, Charney AW, Nadkarni GN, O'Reilly PF, Just AC
(2020) Analysis of hospitalized COVID-19 patients in the Mount
Sinai Health System using electronic medical records (EMR) reveals important prognostic factors for improved clinical outcomes.
medRxiv. https://doi.org/10.1101/2020.04.28.20075788
23. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ,
Balough EM, Aaron JG, Claassen J, Rabbani LE, Hastie J,
Hochman BR (2020) Epidemiology, clinical course, and outcomes
of critically ill adults with COVID-19 in New York City: a prospective cohort study. medRxiv. https://doi.org/10.1101/2020.04.15.
20067157
24. Palaiodimos L, Kokkinidis DG, Li W, Karamanis D, Ognibene J,
Arora S, Southern WN, Mantzoros CS (2020) Severe obesity, increasing age and male sex are independently associated with worse
in-hospital outcomes, and higher in-hospital mortality, in a cohort
of patients with COVID-19 in the Bronx, New York. Metabolism
108:154262. https://doi.org/10.1016/j.metabol.2020.154262
25. Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R,
Klonoff DC (2020) Glycemic characteristics and clinical outcomes
of COVID-19 patients hospitalized in the United States. J Diabetes
Sci Technol 14(4):813–821. https://doi.org/10.1177/
1932296820924469
26. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T,
Davidson KW, Barnaby DP, Becker LB, Chelico JD, Cohen SL,
Cookingham J et al (2020) Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID19 in the New York City area. JAMA 323(20):2052–2059. https://
doi.org/10.1001/jama.2020.6775
27. Department of Health (2020) Diabetes and diabetes prevention.
New York State. https://www.health.ny.gov/diseases/conditions/
diabetes/. Accessed May 23, 2020
28. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H,
Lei CL, Hui DS, Du B (2020) Clinical characteristics of coronavirus
disease 2019 in China. NEJM 382(18):1708–1720
29. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell LF,
Chernyak Y, Tobin K, Cerfolio RJ, Francois F, Horwitz LI
(2020) Factors associated with hospitalization and critical illness
among 4,103 patients with COVID-19 disease in New York City.
medRxiv. https://doi.org/10.1101/2020.04.08.20057794
30. Knapp S (2003) Diabetes and infection: is there a link? A minireview. Gerontology 59(2):99–104
31. Shah BR, Hux JE (2003) Quantifying the risk of infectious diseases
for people with diabetes. Diabetes Care 26(2):510–513
32. Carey IM, Critchley JA, DeWilde S, Harris T, Hosking FJ, Cook
DG (2018) Risk of infection in type 1 and type 2 diabetes compared

Hormones
with the general population: a matched cohort study. Diabetes Care
41(3):513–521
33. Allard R, Leclerc P, Tremblay C, Tannenbaum TN (2010) Diabetes
and the severity of pandemic influenza A (H1N1) infection.
Diabetes Care 33(7):1491–1493
34. Geerlings SE, Hoepelman AI (1999) Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol
26(3–4):259–265
35. Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S, Fadini
GP (2011) Endothelial dysfunction in diabetes: the role of
reparatory mechanisms. Diabetes Care 34(Supplement 2):S285–
S290
36. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R,
Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F,

37.

38.
39.

Moch H (2020) Endothelial cell infection and endotheliitis in
COVID-19. Lancet 395(10234):1417–1418
Escher R, Breakey N, Lämmle B (2020) Severe COVID-19 infection associated with endothelial activation. Thromb Res 190:
62. https://doi.org/10.1016/j.thromres.2020.04.014
Connors JM, Levy JH (2020) COVID-19 and its implications for
thrombosis and anticoagulation. Blood 135(23):2033–2040
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie
D, Moher D, Becker BJ, Sipe TA, Thacker SB (2020) Metaanalysis of observational studies in epidemiology: a proposal for
reporting. JAMA 283(15):2008–2012

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

